What should you know about moderna melanoma vaccine?

Unlike routine vaccines that prevent an infection, a therapeutic melanoma vaccine is designed around tumour-specific information. A sample of the tumour may be analysed so the treatment can present selected targets to the immune system. The aim is to help immune cells recognise abnormal melanoma cells; it is not a substitute for confirming the diagnosis, removing a suitable primary tumour, or staging the disease. Availability, eligibility, and the exact treatment combination depend on regulatory status, the cancer stage, prior treatment, and the specialist team.

Ask the melanoma team whether the vaccine is an approved option, a clinical-trial option, or unavailable in your setting. Clarify how tumour tissue is obtained, whether treatment is combined with immunotherapy, how appointments are scheduled, and what monitoring is required. Keep copies of pathology and staging reports, and tell the team about autoimmune illness, transplant history, medicines, allergies, and previous cancer treatments. Surgery such as excision or sentinel lymph node biopsy may still be part of care when clinically appropriate.

Contact the oncology team urgently for breathing difficulty, facial swelling, widespread rash, severe diarrhoea, persistent vomiting, new confusion, marked weakness, or a high fever after treatment. Immunotherapy can activate the immune system against healthy organs, so new symptoms should be reported rather than self-treated. New neurological symptoms, seizures, severe headache, or sudden weakness require emergency assessment, particularly when melanoma has spread or brain metastases are being evaluated.

Ask what evidence and approval apply where you live, what tumour information is needed, what benefits and harms are realistic for your stage, and how the vaccine fits with surgery, immunotherapy, scans, and follow-up. Ask who to call outside clinic hours if a reaction develops.